Gamida Cell Ltd. - Ordinary Shares (NQ:GMDA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 5, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gamida Cell Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >

Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa

October 10, 2022

From Gamida Cell Ltd.

Via Business Wire

Flotek Industries, Clear Channel Outdoor And 2 Other Penny Stocks Insiders Are Aggressively Buying ↗

October 05, 2022

The Dow Jones jumped by more than 800 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...

Via Benzinga

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting

September 29, 2022

From Gamida Cell Ltd.

Via Business Wire

Recap: Gamida Cell Q2 Earnings ↗

August 15, 2022

Gamida Cell (NASDAQ:GMDA) reported its Q2 earnings results on Monday, August 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗

September 29, 2022

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

September 28, 2022

It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning.

Via InvestorPlace

Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session ↗

September 28, 2022

Gainers

Via Benzinga

Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket ↗

September 28, 2022

Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.

Via Benzinga

Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares

September 28, 2022

From Gamida Cell

Via Business Wire

Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing

September 28, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Announces Launch of Public Offering of Ordinary Shares

September 27, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies

September 19, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting

September 12, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

August 15, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

August 10, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

August 08, 2022

From Gamida Cell Ltd.

Via Business Wire

Earnings Scheduled For August 15, 2022 ↗

August 15, 2022

Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.

Via Benzinga

Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday ↗

August 12, 2022

Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.

Via Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 01, 2022

Via Benzinga

FDA Accepts Gamida's Filing For Stem Cell Transplant Candidate Under Priority Review ↗

August 01, 2022

The U.S. Food and Drug Administration (FDA) has accepted for filing the Gamida Cell’s (NASDAQ: GMDA) Biologics License Application (BLA) for omidubicel in the treatment of patients with blood cancers...

Via Benzinga

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

August 01, 2022

From Gamida Cell Ltd.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

July 22, 2022

During Friday's session, 61 companies made new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

July 25, 2022

On Monday, 100 companies reached new 52-week lows.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

June 16, 2022

It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning.

Via InvestorPlace

27 Stocks Moving in Thursday's Pre-Market Session ↗

June 16, 2022

Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO.

Via Benzinga

Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference

June 13, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors

June 10, 2022

From Gamida Cell

Via Business Wire

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel

June 02, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

June 01, 2022

From Gamida Cell Ltd.

Via Business Wire

Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

June 01, 2022

From Gamida Cell Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.